Perspectives in Thoracic Oncology 2018

Perspectives in Thoracic Oncology - The premier conference for annual updates in lung cancer is organized by Imedex and will be held from Oct 12 - 13, 2018 at New York Marriott Marquis, New York City, New York, United States of America.

The target audience for this medical event is medical and radiation oncologists, thoracic surgeons, nurses, diagnostic radiologists, pathologists, pulmonologists, researchers, and other healthcare professionals interested in the care and treatment of patients with thoracic malignancies.

Conference Description:
For 23 years, this premier gathering of healthcare professionals involved in the treatment of lung cancer continues to differentiate itself from other meetings in the field of thoracic oncology by offering a broad scope of topics essential for practicing oncologists and clinicians. The conference offers a comprehensive update on lung cancer screening and smoking cessation, biomarker testing, management of lung cancer across the spectrum of disease stages and NSCLC, SCLC, mesothelioma, and thoracic tumors. This CME Conference has been approved for a maximum of 12.0 AMA PRA Category 1 Credits.

Conference Highlights:
• Liquid biopsy
• Lung cancer screening
• Smoking cessation
• Locally advanced NSCLC
• Early-stage non-small cell lung cancer (NSCLC)
• Adjuvant therapy
• Mesothelioma
• Squamous cell carcinoma
• Thymic tumors
• The new staging system
• Advanced NSCLC
• Supportive therapy
• Biomarkers and targeted therapy
• Immunotherapy

Learning Objectives:
After attending Perspectives in Thoracic Oncology 2018, participants should be able to:
• Describe the impact of lung cancer staging system revisions, molecular testing guideline updates, novel imaging and diagnostic techniques, and the role of liquid biopsy/cell-free DNA on patient evaluation practices
• Review the current and emerging clinical data regarding the treatment NSCLC that harbor genetic mutations such as EGFR, ALK, ROS1, and less commonly ERBB2, HER2, BRAF, KRAS, MET, TRK, and RET
• Determine the clinical relevance of emerging efficacy and safety data from trials evaluating targeted therapies and immune checkpoint inhibitors (alone or in combination) for NSCLC, SCLC, mesothelioma, and less common thoracic malignancies
• Evaluate the role of current and emerging biomarkers as predictive indicators for treatment selection and patient response
• Translate the latest evidence regarding molecularly targeted agents, immunotherapies, and predictive biomarkers to informed and personalized NSCLC treatment plans

Additional details will be posted as soon as they are available.